Compare DLX & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLX | COLL |
|---|---|---|
| Founded | 1915 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 1994 | 2015 |
| Metric | DLX | COLL |
|---|---|---|
| Price | $23.93 | $36.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $23.00 | ★ $51.40 |
| AVG Volume (30 Days) | ★ 401.2K | 360.6K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.99% | N/A |
| EPS Growth | ★ 52.54 | N/A |
| EPS | ★ 0.77 | 0.40 |
| Revenue | ★ $2,133,200,000.00 | $780,567,000.00 |
| Revenue This Year | $1.35 | $8.01 |
| Revenue Next Year | $1.30 | N/A |
| P/E Ratio | ★ $30.22 | $87.10 |
| Revenue Growth | 0.54 | ★ 23.62 |
| 52 Week Low | $15.41 | $29.19 |
| 52 Week High | $32.07 | $50.79 |
| Indicator | DLX | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 47.31 | 60.89 |
| Support Level | $22.10 | $33.80 |
| Resistance Level | $24.51 | $48.74 |
| Average True Range (ATR) | 0.84 | 1.30 |
| MACD | 0.18 | 0.27 |
| Stochastic Oscillator | 66.80 | 87.86 |
Deluxe Corp is principally a payments and data company. Its reportable segments are: Merchant Services, B2B Payments, Data Solutions, and Print. Maximum revenue is derived from its Print segment, which provides printed personal and business checks, business essentials, as well as branded promotional, print, apparel, and digital storefront solutions. The Merchant Services segment provides electronic credit and debit card authorization, payment systems, and processing services. The B2B segment offers treasury management solutions, integrated accounts payable disbursements, and fraud and security services, and the Data Solutions segment offers data, analytics, and marketing services, as well as financial institution profitability reporting and business incorporation services.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.